First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors



Status:Archived
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:April 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors


This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore the
safety, tolerability, pharmacokinetics, and clinical activity of an investigational drug,
EMD 1204831, in patients with advanced solid tumors who have not responded to previous
therapies or for whom no other therapies are available. Subjects will receive EMD 1204831
twice a day (BID) during each 21-day cycle until disease progression or unacceptable
toxicity.



We found this trial at
1
site
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials